{"url_path":"/sec/alxo/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of matters to a vote of security holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-267472-index.html","accession_number":"0001193125-26-267472","cik":"0001810182","ticker":"ALXO","issuer_name":"ALX ONCOLOGY HOLDINGS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-267472-index.html","primary_entity_key":"0001810182","primary_entity_name":"ALX ONCOLOGY HOLDINGS INC"},"word_count":251,"has_tables":true,"body_markdown":"Item 5.07 Submission of matters to a vote of security holders.\n\nALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.\n\nProposal 1: Election of Two Class II Directors\n\nName of Director\n\n \n\nFor\n\n \n\n \n\nWithheld\n\n \n\n \n\nBroker Non-Votes\n\n \n\nDaniel Curran, M.D.\n\n \n\n \n\n100,933,233\n\n \n\n \n\n \n\n57,798\n\n \n\n \n\n \n\n18,313,833\n\n \n\nRekha Hemrajani\n\n \n\n \n\n82,732,430\n\n \n\n \n\n \n\n18,258,601\n\n \n\n \n\n \n\n18,313,833\n\n \n\nChris Takimoto, M.D., Ph.D., F.A.C.P.\n\n \n\n \n\n100,946,696\n\n \n\n \n\n \n\n44,335\n\n \n\n \n\n \n\n18,313,833\n\n \n\nEach director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.\n\nProposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\nBroker Non-Votes\n\n \n\n \n\n84,540,061\n\n \n\n \n\n \n\n13,497,711\n\n \n\n \n\n \n\n2,953,259\n\n \n\n \n\n \n\n18,313,833\n\n \n\nThe stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.\n\nProposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm\n\nFor\n\n \n\n \n\nAgainst\n\n \n\n \n\nAbstain\n\n \n\n \n\n119,293,775\n\n \n\n \n\n \n\n1,797\n\n \n\n \n\n \n\n9,292\n\n \n\nThe stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nALX ONCOLOGY HOLDINGS INC.\n\n \n\n \n\n \n\n \n\nDate: June 11, 2026\n\nBy:\n\n/s/ Harish Shantharam\n\nHarish Shantharam\n\nChief Financial Officer"}